loader img

Projects

 

TUBITAK TEYDEB 1501 (2024 - )

RECOMBINANT PROTEIN & POLYCLONAL PRIMER ANTIBODY PRODUCTION


Nepenthe has been submitted a Tübitak Teydeb Project in 2023 under calls from TÜBİTAK. Project has been accepted and supported in May 2024 with a grant budget. The period will be 24 months.

The project was for the production of recombinant protein and polyclonal primer antibodies. The target will be global markets.

 

 


 
TUBITAK TEYDEB 1501 (2021 - 2023)

CONJUGATED SECONDARY HUMAN ANTIBODY PRODUCTION


Nepenthe has been submitted a Tübitak Teydeb Project in 2021 under calls from TÜBİTAK. Project has been accepted and supported in July 2021 with a grant budget of 1.336.000 TL. The project completed end of 2023.

The project is for the production of conjugated goat anti-human antibody. In this project 3 different novel flourophores will be sythesized together with a partner and novel conjugation method will be applied. The target will be global POC, ELISA and flow cytometry reagent manufacturers.


 
KOSGEB (2021 - 2022)

RECOMBINANT SARS-CoV-2 SPIKE S1 PRODUCTION


Nepenthe has been submitted a Kosgeb Project in 2021 under the calls of Research & Development, Product Development And Innovation Support Programme. Project has been accepted and supported in 2021 with a qualified staff expences support budget. The project completed at 2022.

The project is for the production of Recombinant SARS-CoV-2 Spike S1 antigen. The target will be global POC and ELISA manufacturers.


 

TUBITAK TEYDEB 1501 (2019 - 2020)

SECONDARY ANTIBODY PRODUCTION


Nepenthe has been submitted a Tübitak Teydeb Project in 2018 under the calls of industrial support programme. Project has been accepted and supported in July 2019 with a grant budget of 1.018.000 TL. The project completed end of 2020.

The project was for the production of goat anti-mouse antibody. The target will be global markets. Some of the production has already been reserved for a US company.


 

Would you like to benefit from our experience right away?

Contact Us
I approve the User Data Protection Law.
Contact Us